A study of a universal CAR-T cell therapy for autoimmune diseases
Treatments studied
Part of Heart & circulation, Immune system & allergy, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your blood counts, liver, kidney, and lung function must meet certain minimum levels.
- You must have a confirmed diagnosis of a specific autoimmune disease such as SLE, ANCA vasculitis, anti-GBM disease, or others listed in the trial.
- For some diseases like lupus or vasculitis, you need to have active disease scores at a certain level.
- You cannot be pregnant and must use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells, to reset the immune system in people with severe autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome. It aims to reduce disease activity and potentially improve quality of life.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
This trial tests a new treatment called RD06-04, which uses your own immune cells modified to target a protein on faulty immune cells. It aims to reduce the autoimmune attack in two rare conditions and may help people who have not found relief from other treatments.
This trial is testing whether a type of immune cell therapy called CAR-T cells can help people with severe autoimmune diseases that have not improved with standard treatments. It may offer a new option for conditions like lupus, Sjogren's syndrome, or vasculitis when other therapies have failed.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hear when a new ANCA Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.